Publicis Health has acquired Payer Sciences, with the ambition that the data-driven health marketing agency will help the group scale up the analytics it offers to clients.
The Publicis Groupe-owned firm said it will lean on Payer Sciences' specialty in helping biopharmaceutical manufacturers navigate the the US reimbursement environment.
The newly-acquired firm was founded in 2009 in New Jersey, it relies on strategic and analytic insights to aid decision making for pharma clients, with a backbone of 40 full-time data analysts, payer experts, and B2B communications specialists.
Alexandra von Plato, chief executive of Publicis Health, said: "Payer Sciences' powerful suite of unique software and services enables clients to target and optimize interactions with the entire ecosystem of reimbursement stakeholders, including health plans, insurers, pharmacy benefit managers, and other organizations that design or administer pharmacy and medical benefits.
"Beyond biopharmaceuticals, Payer Science's proprietary technology and methodologies have practical applications for other Groupe clients and industries to uncover greater insights from data that will help convert payers and buyers in non-pharma categories as well. The addition of Payer Sciences strengthens Publicis Health's offering to become our clients' trusted transformation partner."
Eric Colwell, principal of Payer Sciences, added: "In today's complex payer marketplace, we understand that the traditional methods of payer marketing no longer work.
"We've transformed payer marketing for the 21st century by harnessing data and advanced analytics to help our clients extract deeper insights into payer behavior. We are delighted to join the Publicis Groupe family and look forward to redefining payer marketing."
Publicis Groupe did not disclose the acquisition fee.